Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.
暂无分享,去创建一个
J. Larghero | P. Berthaud | P. Rousselot | F. Mahon | F. Calvo | C. Chomienne | S. Mourah | E. Raffoux | L. Degos | J. Marolleau | A. Taksin | T. Leguay | J. Bastie | I. Madelaine-Chambrin
[1] Claude Preudhomme,et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. , 2002, Blood.
[2] R. Larson,et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.
[3] R. Herrmann,et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. , 2002, Blood.
[4] M. Baccarani,et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.
[5] S. de Vos,et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. , 2002, Blood.
[6] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[7] C. Peschel,et al. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study , 2002, The Lancet.
[8] Kevin D. Smith,et al. Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. , 2002, Blood.
[9] C. Barthe,et al. Roots of clinical resistance to STI-571 cancer therapy. , 2001, Science.
[10] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[11] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[12] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[13] F. Rossi,et al. Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease , 2001, British journal of haematology.
[14] J. Melo,et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.
[15] S. Urien,et al. Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer. , 2000, Clinical biochemistry.
[16] M. Varella‐Garcia,et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.
[17] K. Uozumi,et al. Expression of the multidrug transporter, P‐glycoprotein, in chronic myelogenous leukaemia cells in blast crisis , 1990, British journal of haematology.
[18] H. Kantarjian,et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. , 2002, Blood.
[19] J. Griffin,et al. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. , 2000, Blood.
[20] M. Zucchetti,et al. Role of (cid:1) 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI571 , 2000 .